Appropriateness of breast‐conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic‐based series
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although BRCA1 and BRCA2 were identified in 1994 and 1995, respectively, to the authors' knowledge the optimal management of women with BRCA‐associated breast carcinoma remains incompletely defined. The current study evaluates the appropriateness of breast‐conserving therapy (BCT) in women with BRCA mutations. METHODS: Between May 1992 and October 2003, 87 female participants in genetic testing protocols were identified who 1) were found to have deleterious germline BRCA mutations and 2) reported a history of invasive breast carcinoma that was treated with wide local excision and radiation therapy. Clinical records were reviewed and follow‐up was updated. RESULTS: The 87 subjects underwent BCT for 95 invasive breast tumors (8 women received BCT for metachronous bilateral tumors). In all 95 treated breasts, the 5‐year and 10‐year probabilities of metachronous ipsilateral breast carcinoma (MIBC) were 11.2% and 13.6%, respectively. Among the 87 subjects, the 5‐year and 10‐year probabilities of metachronous contralateral breast carcinoma (CBC) after treatment of the index tumor were 11.9% and 37.6%. No clinical factors were identified that were associated with either MIBC or CBC, including the use of tamoxifen or chemotherapy. CONCLUSIONS: Women with BRCA‐associated breast carcinoma who undergo BCT appear to have risks of MIBC that are similar to those reported for young women without known mutations. The indications for unilateral mastectomy in this group of women should be the same as those for women with nonhereditary carcinoma. However, significant risks of CBC and possibly late MIBC may prompt the serious consideration of bilateral mastectomy as a preventive measure. Cancer 2005. © 2004 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status
Haffty, B. G., Harrold, E., Khan, A. J., Pathare, P., Smith, T. E., Turner, B. C., Glazer, P. M., Ward, B., Carter, D., Matloff, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08434-9 · Cited by 307
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
Self-citation
Research works printed but not linked: 24
- 10.1126/science.7545954 · DOI · Paper page
- 10.1038/378789a0 · DOI · Paper page
- 10.1053/srao.2002.35254 · DOI
- Foulkes WD, 1997, Germ‐line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer, Clin Cancer Res, 3, 2465
- 10.1016/S0167-8140(98)00023-1 · DOI
- 10.1093/jnci/91.24.2112 · DOI · Paper page
- 10.1200/JCO.2000.18.19.3360 · DOI · Paper page
- Pierce L, 2003, Ten‐year outcome of breast‐conserving surgery (BCS) and radiotherapy (RT) in women with breast cancer (BC) and germline BRCA 1/2 mutations: results from an international collaboration [abstract], Breast Cancer Res Treat, 82, S7
- Delaloge S, 2003, Young age is the major predictor of local relapse among conservatively treated BRCA1‐, BRCA2‐, or non‐BRCA‐linked hereditary breast cancer (BC) [abstract], Proc Am Soc Clin Oncol, 22, 11
- 10.1200/JCO.2004.04.033 · DOI · Paper page
- 10.1200/JCO.1999.17.10.3017 · DOI · Paper page
- Bremer M, 2003, Local relapse after post‐operative radiotherapy in patients with bilateral breast cancer by BRCA1/2 status [abstract], Proc Am Soc Clin Oncol, 22, 11
- 10.1016/j.ejca.2004.01.017 · DOI
- 10.1200/JCO.2002.02.026 · DOI · Paper page
- 10.1200/JCO.1998.16.6.2045 · DOI
- 10.1016/S0360-3016(00)00761-6 · DOI
- Haas JA, 1998, An analysis of age and family history on outcome after breast‐conservation treatment: the University of Pennsylvania experience, Cancer J Sci Am, 4, 308
- Harrold EV, 1998, Local recurrence in the conservatively treated breast cancer patient: a correlation with age and family history, Cancer J Sci Am, 4, 302
- Simmonds P, 1999, Is breast conservation appropriate for women with hereditary breast cancer [abstract]?, Proc Am Soc Clin Oncol, 18, 612a
- 10.1007/BF02557530 · DOI
- 10.1054/bjoc.2000.1239 · DOI · Paper page
- Foulkes WD, 1998, BRCA mutations and survival in breast cancer, J Clin Oncol, 16, 3206, 10.1200/JCO.1998.16.9.3206 · doi:10.1200/jco.1998.16.9.3206
- 10.1016/S0140-6736(05)79091-7 · DOI
- 10.1200/JCO.1998.16.5.1642 · DOI · Paper page
Cited by
Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Graeser, M. K., Engel, C., Rhiem, K., Gadzicki, D., Bick, U., Kast, K., Froster, U. G., Schlehe, B., Bechtold, A., Arnold, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9430 · Cited by 314
Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging
Plevritis, S. K., Kurian, A. W., Sigal, B. M., Daniel, B. L., Ikeda, D. M., Stockdale, F. E., & Garber, A. M. (2006) · JAMA · doi:10.1001/jama.295.20.2374 · Cited by 260
Malone, K. E., Begg, C. B., Haile, R. W., Borg, A., Concannon, P., Tellhed, L., Xue, S., Teraoka, S., Bernstein, L., Capanu, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2495 · Cited by 191
van den Broek, A. J., van ’t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., Smit, V. T. H. B. M., Cornelisse, C. J., van Beek, M., Janssen-Heijnen, M. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3942 · Cited by 104
Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?
Garcia-Etienne, C. A., Barile, M., Gentilini, O. D., Botteri, E., Rotmensz, N., Sagona, A., Farante, G., Galimberti, V., Luini, A., Veronesi, P., et al. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0638-7 · Cited by 100
Metadata
- Authors
- Robson, M., Svahn, T., McCormick, B., Borgen, P., A. Hudis, C., Norton, L., & Offit, K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004-11-22
- Volume
- 103
- Issue
- 1
- Pages
- 44-51
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1995498471
- Cited by
- 126
- References
- 3
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Appropriateness of breast‐conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic‐based series. https://app.cochat.ai/papers/10.1002/cncr.20728
- The paper
- Robson, M., Svahn, T., McCormick, B., Borgen, P., A. Hudis, C., Norton, L., & Offit, K. (2005). Appropriateness of breast‐conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic‐based series. Cancer. https://doi.org/10.1002/cncr.20728
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.